BridgeBio Oncology Therapeutics, Inc.
BBOT Nasdaq
SEC CIK 1869105
Follow BridgeBio Oncology Therapeutics
Weekly email: filings, results
Net income
−$34.2M
+23.6% vs same quarter last year
EPS, diluted
−$0.43
+58.3% vs same quarter last year
Operating cash flow
−$28.4M
+1.4% vs same quarter last year
Operating income
−$37.5M
+23.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$134M |
| FY24 | −$74.3M |
| FY23 | −$41.7K |
| FY22 | - |